Wealth Dimensions Group Ltd. Increases Stock Position in Pfizer Inc. (NYSE:PFE)

Wealth Dimensions Group Ltd. increased its position in Pfizer Inc. (NYSE:PFE – Get Rating) by 6.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,732 shares of the biopharmaceutical company’s stock after purchasing an additional 1,089 shares during the quarter. Wealth Dimensions Group Ltd.’s holdings in Pfizer were worth $909,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in PFE. Lam Group Inc. bought a new stake in Pfizer in the 4th quarter valued at about $25,000. Worth Asset Management LLC bought a new stake in Pfizer in the 1st quarter valued at about $29,000. My Personal CFO LLC bought a new stake in shares of Pfizer during the 4th quarter worth about $32,000. Mendota Financial Group LLC bought a new stake in shares of Pfizer during the 4th quarter worth about $33,000. Finally, Capital Directions Investment Advisors LLC bought a new stake in shares of Pfizer during the 4th quarter worth about $36,000. 67.62% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, major shareholder Pfizer Inc purchased 1,811,594 shares of Pfizer stock in a transaction that occurred on Friday, March 17th. The shares were acquired at an average price of $2.76 per share, for a total transaction of $4,999,999.44. Following the transaction, the insider now directly owns 5,952,263 shares in the company, valued at $16,428,245.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Pfizer news, major shareholder Pfizer Inc bought 1,811,594 shares of the business’s stock in a transaction on Friday, March 17th. The shares were bought at an average cost of $2.76 per share, for a total transaction of $4,999,999.44. Following the transaction, the insider now owns 5,952,263 shares in the company, valued at approximately $16,428,245.88. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Scott Gottlieb bought 1,000 shares of the business’s stock in a transaction on Friday, May 5th. The shares were acquired at an average price of $38.42 per share, for a total transaction of $38,420.00. Following the completion of the transaction, the director now owns 5,000 shares in the company, valued at approximately $192,100. The disclosure for this purchase can be found here. Insiders have purchased a total of 1,813,594 shares of company stock worth $5,076,999 in the last 90 days. Corporate insiders own 0.05% of the company’s stock.

Pfizer Price Performance

Shares of PFE traded down $0.06 during trading hours on Friday, hitting $37.77. The stock had a trading volume of 9,321,134 shares, compared to its average volume of 23,905,904. The company’s fifty day moving average is $39.57 and its two-hundred day moving average is $44.18. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.37 and a quick ratio of 1.11. Pfizer Inc. has a 52 week low of $36.17 and a 52 week high of $54.93. The stock has a market capitalization of $213.22 billion, a price-to-earnings ratio of 7.44, a P/E/G ratio of 1.28 and a beta of 0.63.

Pfizer (NYSE:PFE – Get Rating) last issued its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.23. The business had revenue of $18.28 billion for the quarter, compared to the consensus estimate of $16.49 billion. Pfizer had a net margin of 31.25% and a return on equity of 37.53%. The firm’s quarterly revenue was down 28.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.62 EPS. On average, analysts anticipate that Pfizer Inc. will post 3.35 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 9th. Investors of record on Friday, May 12th will be given a dividend of $0.41 per share. The ex-dividend date is Thursday, May 11th. This represents a $1.64 annualized dividend and a yield of 4.34%. Pfizer’s dividend payout ratio (DPR) is 32.28%.

Analyst Ratings Changes

Several brokerages have recently issued reports on PFE. UBS Group lowered their price objective on shares of Pfizer from $41.00 to $39.00 in a research note on Friday, May 5th. StockNews.com began coverage on shares of Pfizer in a research note on Thursday, May 18th. They issued a “buy” rating on the stock. SVB Leerink lowered their price objective on shares of Pfizer from $49.00 to $48.00 and set a “market perform” rating on the stock in a research note on Wednesday, February 1st. Berenberg Bank set a $40.00 target price on shares of Pfizer in a research report on Tuesday, February 7th. Finally, Bank of America dropped their target price on shares of Pfizer from $50.00 to $45.00 and set a “neutral” rating on the stock in a research report on Friday, April 21st. Nine research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $47.33.

Pfizer Company Profile

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.